Ibrutinib 420 mg

DRUG3 trials

Conditions

Autoimmune Hemolytic AnemiaBreast NeoplasmsChronic Lymphocytic LeukemiaLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-CellMalignant Neoplasm of BreastMonoclonal B-Cell Lymphocytosis CLL-TypeSmall Lymphocytic Lymphoma

Phase 1

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Active, not recruitingNCT03379428

US Oncology ResearchBreast Neoplasms, Malignant Neoplasm of Breast

Start: 2017-11-29End: 2025-01-31Updated: 2024-12-06

Phase 2

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

RecruitingNCT05694312

Gruppo Italiano Malattie EMatologiche dell'AdultoAutoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis CLL-Type +1

Start: 2023-11-24End: 2026-11-30Target: 45Updated: 2023-12-01

Phase 4

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

CompletedNCT03190330

Johnson & Johnson Private LimitedLeukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Start: 2019-06-26End: 2023-05-03Updated: 2025-05-25

Related Papers

A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer

Cancer Medicine2026-07-27

Abstract PO1-04-03: Phase I/II Trial of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer